Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

This is a longitudinal, observational, prospective, multicentre, cohort study, conducted in France among a representative sample of public and/or private hospital-based oncologists. Data will be collected by the investigator during three visits using data available in the patient medical record and obtained from patient questioning and clinical examination performed during the consultations: * Baseline visit: prescription of Nivestim®. * Follow-up visit: during the first cycle of chemotherapy after the first course of Nivestim®. * Final visit: after the last cycle of chemotherapy or 16-18 weeks after inclusion.